![Lonza Group AG Website](https://cdn.finchat.io/631759.png)
Lonza Group AG
SWX-LONN
Company Overview
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Name
Lonza Group AG
CEO
Dr. Wolfgang Wienand Ph.D.
Website
www.lonza.com
Sector
Life Sciences Tools and Services
Year Founded
1897
Profile
Market Cap
CHF 38.73B
EV
CHF 40.57B
Shares Out
72.23M
Revenue
CHF 6,696M
Employees
17,834
Margins
Gross
36.01%
EBITDA
27.48%
Operating
19.74%
Pre-Tax
10.44%
Net
8.56%
FCF
0.28%
Returns (5Yr Avg)
ROA
8.05%
ROTA
18.84%
ROE
15.03%
ROCE
8.34%
ROIC
6.9%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
CHF 623.67
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
CHF 2,017M
Net Debt
CHF 1,778M
Debt/Equity
0.4
EBIT/Interest
6.74
Growth (CAGR)
Rev 3Yr
11.68%
Rev 5Yr
3.19%
Rev 10Yr
6.28%
Dil EPS 3Yr
-5.95%
Dil EPS 5Yr
5.35%
Dil EPS 10Yr
8.34%
Rev Fwd 2Yr
6.92%
EBITDA Fwd 2Yr
4.34%
EPS Fwd 2Yr
16.19%
EPS LT Growth Est
16.44%
Dividends
Yield
—
Payout
50.48%
DPS
CHF 4
DPS Growth 3Yr
10.06%
DPS Growth 5Yr
7.78%
DPS Growth 10Yr
6.41%
DPS Growth Fwd 2Yr
15.45%